25-NB

General structure of 25-NB derivatives, where R is usually 2,5-dimethoxy-4-(alkyl or halogen), R₁ is usually H but rarely methyl, and Cyc is usually 2-substituted phenyl but can be other heterocycles.

The 25-NB (25x-NBx) series, or NBOMe series, also known as the N-benzylphenethylamines, is a family of serotonergic psychedelics. ^{[1] [2]} They are substituted phenethylamines and were derived from the 2C family. ^[2] The most commonly encountered NBOMe drugs are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. ^[3]

The NBOMe drugs act as selective agonists of the serotonin 5-HT₂ receptors. ^{[4] [5] [6] [7] [8] [9] [10]} The 25-NB family is unique relative to other classes of psychedelics in that they are, generally speaking, extremely potent and quite selective for the 5-HT₂ receptors. ^[2]

Use of NBOMe series drugs has caused many deaths and hospitalisations since the drugs popularisation in the 2010s. This is primarily due to their high potency, unpredictable pharmacokinetics, and sellers passing off the compounds in the series as LSD. ^[11]

Pharmacology

Pharmacodynamics

Actions

The NBOMe drugs are highly potent and selective agonists of the serotonin 5-HT₂ receptors, including of the 5-HT_2A, 5-HT_2B, and 5-HT_2C receptors. ^{[1] [3] [12] [13]} However, they are much less potent and efficacious at the serotonin 5-HT_2B receptor compared to the serotonin 5-HT_2A and 5-HT_2C receptors. ^[3] The drugs are highly selective for the serotonin 5-HT₂ receptors over other serotonin receptors and over a variety of other biological targets. ^{[1] [3] [12] [13]} They are likewise inactive as monoamine reuptake inhibitors and releasing agents. ^[12] Many of the NBOMe drugs are partial agonists of the rat and mouse trace amine-associated receptor 1 (TAAR1), but they are inactive as agonists of the human TAAR1. ^[14]

Effects

In accordance with their psychedelic effects, NBOMe drugs induce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. ^[15] They have also been found to produce hyperlocomotion at low doses and hypolocomotion at high doses in rodents. ^[15]

Unlike most other serotonergic psychedelics, the NBOMe drugs 25B-NBOMe and 25N-NBOMe have been found to produce reinforcing effects in rodents, and hence may have misuse potential. ^{[3] [16] [17]} Relatedly, 25B-NBOMe robustly increased dopamine levels in the nucleus accumbens similarly to methamphetamine. ^{[18] [16]} The reinforcing effects of 25B-NBOMe were not blocked by serotonin 5-HT_2A receptor antagonism, and it is unclear how they are produced. ^{[18] [16]} However, some NBOMe drugs, such as 25N-NBOMe, have been found to increase phosphorylation of the dopamine transporter (DAT) in the striatum similarly to methamphetamine in rodents. ^{[19] [17]} DAT phosphorylation is associated with dopamine reverse transport and efflux, which in turn increases extracellular dopamine levels. ^{[19] [17]}

Similarly to other psychedelics like DOI and 2C-T-7, tolerance has been found to gradually develop to the head-twitch response induced by 25I-NBOMe with chronic administration in rodents. ^{[15] [20]}

Toxicity and harm potential

NBOMe compounds are often associated with life-threatening toxicity and death. ^{[21] [22]} Studies on NBOMe family of compounds demonstrated that the substance exhibit neurotoxic and cardiotoxic activity. ^[3] Reports of autonomic dysfunction remains prevalent with NBOMe compounds, with most individuals experiencing sympathomimetic toxicity such as vasoconstriction, hypertension and tachycardia in addition to hallucinations. ^{[23] [24] [25] [26] [27]} Other symptoms of toxidrome include agitation or aggression, seizure, hyperthermia, diaphoresis, hypertonia, rhabdomyolysis, and death. ^{[23] [27] [22]} Researchers report that NBOMe intoxication frequently display signs of serotonin syndrome. ^[28] The likelihood of seizure is higher in NBOMes compared to other psychedelics. ^[3]

NBOMe and NBOHs are regularly sold as LSD in blotter papers, ^{[22] [29]} which have a bitter taste and different safety profiles. ^{[23] [21]} Despite high potency, recreational doses of LSD have only produced low incidents of acute toxicity. ^[21] Fatalities involved in NBOMe intoxication suggest that a significant number of individuals ingested the substance which they believed was LSD, ^[25] and researchers report that "users familiar with LSD may have a false sense of security when ingesting NBOMe inadvertently". ^[23] While most fatalities are due to the physical effects of the drug, there have also been reports of death due to self-harm and suicide under the influence of the substance. ^{[30] [31] [23]}

Given limited documentation of NBOMe consumption, the long-term effects of the substance remain unknown. ^[23] NBOMe compounds are not active orally, ^[a] and are usually taken sublingually. ^{[2] : 3} When NBOMes are administered sublingually, numbness of the tongue and mouth followed by a metallic chemical taste was observed, and researchers describe this physical side effect as one of the main discriminants between NBOMe compounds and LSD. ^{[33] [34] [35]}

Neurotoxic and cardiotoxic actions

Many of the NBOMe compounds have high potency agonist activity at additional 5-HT receptors and prolonged activation of 5-HT_2B can cause cardiac valvulopathy in high doses and chronic use. ^{[22] [26]} 5-HT_2B receptors have been strongly implicated in causing drug-induced valvular heart disease. ^{[36] [37] [38]} The high affinity of NBOMe compounds for adrenergic α₁ receptor has been reported to contribute to the stimulant-type cardiovascular effects. ^[26]

In vitro studies, 25C-NBOMe has been shown to exhibit cytotoxicity on neuronal cell lines SH-SY5Y, PC12, and SN471, and the compound was more potent than methamphetamine at reducing the visibility of the respective cells; the neurotoxicity of the compound involves activation of MAPK/ERK cascade and inhibition of Akt/PKB signaling pathway. ^[3] 25C-NBOMe, including the other derivative 25D-NBOMe, reduced the visibility of cardiomyocytes H9c2 cells, and both substances downregulated expression level of p21 (CDC24/RAC)-activated kinase 1 (PAK1), an enzyme with documented cardiac protective effects. ^[3]

Preliminary studies on 25C-NBOMe have shown that the substance is toxic to development, heart health, and brain health in zebrafish, rats, and Artemia salina , a common organism for studying potential drug effects on humans, but more research is needed on the topic, the dosages, and if the toxicology results apply to humans. Researchers of the study also recommended further investigation of the drug's potential in damaging pregnant women and their fetus due to the substance's damaging effects to development. ^{[39] [40]}

Emergency treatment

At present, there are no specific antidotes for NBOMes, and all acute intoxication is managed by symptomatic treatments, such as administration of benzodiazepines, antipsychotic drugs, and antiarrhythmic agents, such as beta blockers; some emergency interventions are intended to specifically treat rhabdomyolysis, which may lead to critical complications such as metabolic acidosis and acute kidney injury. ^[3]

Chemical structure

The 25-NB compounds are mostly N-benzylphenethylamines, ^{[2] [1]} though in some cases the phenyl ring of the N-benzyl group is replaced by other heterocycles such as thiophene, pyridine, furan, tetrahydrofuran, benzodioxole or naphthalene, among others. ^{[41] [42]}

Generally speaking, they have methoxy groups at the 2 and 5 positions of the phenyl ring, a substitution such as a halogen or alkyl group at the 4 position of the phenyl ring, and a methoxy or other substitution (e.g., hydroxyl, fluoro) at the 2 position of the N-benzyl ring. ^[2] More rarely, other substitution patterns may be present ^{[43] [44]} (see e.g. NBOMe-mescaline, 25G-NBOMe, 2CBFly-NBOMe, 25C-NB3OMe). They differ from the 2C series by the presence of the N-benzyl moiety. ^[2]

Rarely an alpha-methyl group is present making them N-benzyl amphetamines rather than N-benzyl phenethylamines, but this greatly reduces potency and activity. However in some cases where a side chain methyl group is cyclised back to the ring (e.g. in 2CBCB-NBOMe) or links the two alpha positions (e.g. in DMBMPP), this can improve selectivity for the 5-HT_2A receptor subtype. ^[45]

List of 25-NB derivatives

25I-NBOMe, the most well-known 25-NB derivative

This list includes notable compounds representative of most of the structural variations that have been explored in this series, but is by no means exhaustive. Many derivatives invented for scientific study into the structure-activity relationships of 5-HT₂ receptor agonists have never appeared as designer drugs, while conversely some derivatives that have appeared as designer drugs are structurally novel and of unknown pharmacological activity (e.g. C30-NBOMe, 5-APB-NBOMe).

Chemical structure	Common name	Chemical name	CAS number	R	R1	Cyc
	25B-NB	N-benzyl-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	155639-26-2	2,5-dimethoxy-4-bromo	H	phenyl
	25C-NB	N-benzyl-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane	1391487-65-2	2,5-dimethoxy-4-chloro	H	phenyl
	25I-NB	N-benzyl-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	919797-18-5	2,5-dimethoxy-4-iodo	H	phenyl
	25I-NMeTh	N-[(thiophen-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	1391499-03-8	2,5-dimethoxy-4-iodo	H	thiophen-2-yl
	25B-NMePyr	N-[(pyridin-2-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1391499-21-0	2,5-dimethoxy-4-bromo	H	pyridin-2-yl
	25I-NMeFur	N-[(furan-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	1391498-93-3	2,5-dimethoxy-4-iodo	H	furan-2-yl
	25I-NMeTHF	N-[(tetrahydrofuran-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane		2,5-dimethoxy-4-iodo	H	tetrahydrofuran-2-yl
	25B-NBF	N-(2-fluorobenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1539266-17-5	2,5-dimethoxy-4-bromo	H	2-fluorophenyl
	25B-NBOH	N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1335331-46-8	2,5-dimethoxy-4-bromo	H	2-hydroxyphenyl
	25B-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1026511-90-9	2,5-dimethoxy-4-bromo	H	2-methoxyphenyl
	25B-NB23DM	N-(2,3-dimethoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1391493-68-7	2,5-dimethoxy-4-bromo	H	2,3-dimethoxyphenyl
	25B-NB25DM	N-(2,5-dimethoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane		2,5-dimethoxy-4-bromo	H	2,5-dimethoxyphenyl
	25B-NMe7BF	N-[(benzofuran-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1391492-46-8	2,5-dimethoxy-4-bromo	H	benzofuran-7-yl
	25B-NMe7DHBF	N-[(2,3-dihydrobenzofuran-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1391492-40-2	2,5-dimethoxy-4-bromo	H	2,3-dihydrobenzofuran-7-yl
	25B-NMe7BT	N-[(benzothiophen-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1391492-59-3	2,5-dimethoxy-4-bromo	H	benzothiophen-7-yl
	25B-NMe7Box	N-[(benzoxazol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1391498-73-9	2,5-dimethoxy-4-bromo	H	benzoxazol-7-yl
	25B-NMe7Ind	N-[(indol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1391498-28-4	2,5-dimethoxy-4-bromo	H	indol-7-yl
	25B-NMe7Indz	N-[(indazol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1391498-43-3	2,5-dimethoxy-4-bromo	H	indazol-7-yl
	25B-NMe7Bim	N-[(benzimidazol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1391498-62-6	2,5-dimethoxy-4-bromo	H	benzimidazol-7-yl
	FECIMBI-36	N-[(2-fluoroethoxy)benzyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane		2,5-dimethoxy-4-bromo	H	2-(2-fluoroethoxy)phenyl
	DOB-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane		2,5-dimethoxy-4-bromo	methyl	2-methoxyphenyl
	25C-NB3OMe	N-(3-methoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane	1566571-34-3	2,5-dimethoxy-4-chloro	H	3-methoxyphenyl
	25C-NB4OMe	N-(4-methoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane	1566571-35-4	2,5-dimethoxy-4-chloro	H	4-methoxyphenyl
	C30-NBOMe	N-(3,4,5-trimethoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane	1445574-98-0	2,5-dimethoxy-4-chloro	H	3,4,5-trimethoxyphenyl
	25C-NBF	N-(2-fluorobenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane	1539266-21-1	2,5-dimethoxy-4-chloro	H	2-fluorophenyl
	25C-NBCl	N-(2-chlorobenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane		2,5-dimethoxy-4-chloro	H	2-chlorophenyl
	25C-NBOH	N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane	1391488-16-6	2,5-dimethoxy-4-chloro	H	2-hydroxyphenyl
	25C-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane	1227608-02-7	2,5-dimethoxy-4-chloro	H	2-methoxyphenyl
	25C-NBOEt	N-(2-ethoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane		2,5-dimethoxy-4-chloro	H	2-ethoxyphenyl
	25C-NBOiPr	N-(2-isopropoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane		2,5-dimethoxy-4-chloro	H	2-isopropoxyphenyl
	25F-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-fluorophenyl)-2-aminoethane	1373917-84-0	2,5-dimethoxy-4-fluoro	H	2-methoxyphenyl
	25CN-NBOH	N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-cyanophenyl)-2-aminoethane	1539266-32-4	2,5-dimethoxy-4-cyano	H	2-hydroxyphenyl
	25CN-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-cyanophenyl)-2-aminoethane	1354632-16-8	2,5-dimethoxy-4-cyano	H	2-methoxyphenyl
	25D-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminoethane	1354632-02-2	2,5-dimethoxy-4-methyl	H	2-methoxyphenyl
	25D-NBOH	N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminoethane	1391488-44-0	2,5-dimethoxy-4-methyl	H	2-hydroxyphenyl
	25E-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-ethylphenyl)-2-aminoethane	1354632-14-6	2,5-dimethoxy-4-ethyl	H	2-methoxyphenyl
	25E-NBOH	N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-ethylphenyl)-2-aminoethane	1391489-79-4	2,5-dimethoxy-4-ethyl	H	2-hydroxyphenyl
	25G-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-3,4-dimethylphenyl)-2-aminoethane	1354632-65-7	2,5-dimethoxy-3,4-dimethyl	H	2-methoxyphenyl
	25H-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxyphenyl)-2-aminoethane	1566571-52-5	2,5-dimethoxy	H	2-methoxyphenyl
	25I-NB34MD	N-(3,4-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	1391497-81-6	2,5-dimethoxy-4-iodo	H	3,4-methylenedioxyphenyl
	25I-NB3OMe	N-(3-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	1566571-40-1	2,5-dimethoxy-4-iodo	H	3-methoxyphenyl
	25I-NB4OMe	N-(4-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	1566571-41-2	2,5-dimethoxy-4-iodo	H	4-methoxyphenyl
	25I-NBF	N-(2-fluorobenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	919797-21-0	2,5-dimethoxy-4-iodo	H	2-fluorophenyl
	25I-NBBr	N-(2-bromobenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	1648649-98-2	2,5-dimethoxy-4-iodo	H	2-bromophenyl
	25I-NBTFM	N-[2-(trifluoromethyl)benzyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane		2,5-dimethoxy-4-iodo	H	2-(trifluoromethyl)phenyl
	25I-NBMD	N-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	919797-25-4	2,5-dimethoxy-4-iodo	H	2,3-methylenedioxyphenyl
	25B-NBMD	N-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane	1354632-19-1	2,5-dimethoxy-4-bromo	H	2,3-methylenedioxyphenyl
	25C-NBMD	N-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane	1373879-26-5	2,5-dimethoxy-4-chloro	H	2,3-methylenedioxyphenyl
	25D-NBMD	N-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminoethane	1391488-97-3	2,5-dimethoxy-4-methyl	H	2,3-methylenedioxyphenyl
	25I-NBOH	N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	919797-20-9	2,5-dimethoxy-4-iodo	H	2-hydroxyphenyl
	25I-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	919797-19-6	2,5-dimethoxy-4-iodo	H	2-methoxyphenyl
	DOI-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane		2,5-dimethoxy-4-iodo	methyl	2-methoxyphenyl
	25I-NBMeOH	N-[2-(hydroxymethyl)benzyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	1391494-71-5	2,5-dimethoxy-4-iodo	H	2-(hydroxymethyl)phenyl
	25I-NBAm	N-[2-(carbamoyl)benzyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	1391494-85-1	2,5-dimethoxy-4-iodo	H	2-(carbamoyl)phenyl
	25I-NMe7DHBF	N-[(2,3-dihydrobenzofuran-7-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane		2,5-dimethoxy-4-iodo	H	2,3-dihydrobenzofuran-7-yl
	25I-N2Nap1OH	N-[(1-hydroxynaphthalen-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane		2,5-dimethoxy-4-iodo	H	1-hydroxynaphthalen-2-yl
	25I-N3MT2M	N-[(3-methoxythiophen-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	1354632-66-8	2,5-dimethoxy-4-iodo	H	3-methoxythiophen-2-yl
	25I-N4MT3M	N-[(4-methoxythiophen-3-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane	1354632-73-7	2,5-dimethoxy-4-iodo	H	4-methoxythiophen-3-yl
	25iP-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-isopropylphenyl)-2-aminoethane	1391487-83-4	2,5-dimethoxy-4-isopropyl	H	2-methoxyphenyl
	25N-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane	1354632-03-3	2,5-dimethoxy-4-nitro	H	2-methoxyphenyl
	25N-NBOEt [46]	N-(2-ethoxybenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane		2,5-dimethoxy-4-nitro	H	2-ethoxyphenyl
	25N-NB-2-OH-3-Me	N-(2-hydroxy-3-methylbenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane		2,5-dimethoxy-4-nitro	H	2-hydroxy-3-methylphenyl
	25N-NBOCF2H	N-(2-difluoromethoxybenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane		2,5-dimethoxy-4-nitro	H	2-difluoromethoxyphenyl
	25N-NBPh [47]	N-[(2-phenyl)benzyl]-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane		2,5-dimethoxy-4-nitro	H	o-biphenyl
	25N-N1-Nap	N-[(naphthalen-1-yl)methyl]-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane		2,5-dimethoxy-4-nitro	H	1-naphthyl
	25P-NBOMe	N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-propylphenyl)-2-aminoethane	1391489-07-8	2,5-dimethoxy-4-propyl	H	2-methoxyphenyl
	25P-NBOH	N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-propylphenyl)-2-aminoethane	1391490-34-8	2,5-dimethoxy-4-propyl	H	2-hydroxyphenyl
	25TFM-NBOMe	N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(trifluoromethyl)phenyl]-2-aminoethane	1027161-33-6	2,5-dimethoxy-4-(trifluoromethyl)	H	2-methoxyphenyl
	25O-NBcP	N-(2-cyclopropylbenzyl)-1-(2,4,5-trimethoxyphenyl)-2-aminoethane		2,4,5-trimethoxy	H	2-cyclopropylphenyl
	25T-NBOMe	N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(methylthio)phenyl]-2-aminoethane	1539266-47-1	2,5-dimethoxy-4-(methylthio)	H	2-methoxyphenyl
	25T2-NBOMe	N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(ethylthio)phenyl]-2-aminoethane	1539266-51-7	2,5-dimethoxy-4-(ethylthio)	H	2-methoxyphenyl
	25T4-NBOMe	N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(isopropylthio)phenyl]-2-aminoethane	1354632-17-9	2,5-dimethoxy-4-(isopropylthio)	H	2-methoxyphenyl
	25T7-NBOMe	N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(propylthio)phenyl]-2-aminoethane	1539266-55-1	2,5-dimethoxy-4-(propylthio)	H	2-methoxyphenyl
	25T7-NBOH	N-(2-hydroxybenzyl)-1-[2,5-dimethoxy-4-(propylthio)phenyl]-2-aminoethane	1354632-41-9	2,5-dimethoxy-4-(propylthio)	H	2-hydroxyphenyl
	25AM-NBOMe [48]	N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-pentylphenyl]-2-aminoethane		2,5-dimethoxy-4-(n-pentyl)	H	2-methoxyphenyl
	NBOMe-mescaline	N-(2-methoxybenzyl)-1-(3,4,5-trimethoxyphenyl)-2-aminoethane	1354632-01-1	3,4,5-trimethoxy	H	2-methoxyphenyl
	NBOMe-escaline	N-(2-methoxybenzyl)-1-(3,5-dimethoxy-4-ethoxyphenyl)-2-aminoethane		3,5-dimethoxy-4-ethoxy	H	2-methoxyphenyl
	NBOMe-thiobuscaline	N-(2-methoxybenzyl)-1-(3,5-dimethoxy-4-butylthiophenyl)-2-aminoethane		3,5-dimethoxy-4-(n-butylthio)	H	2-methoxyphenyl
	MDPEA-NBOMe	N-(2-methoxybenzyl)-1-(3,4-methylenedioxyphenyl)-2-aminoethane		3,4-methylenedioxy	H	2-methoxyphenyl
	2C2-NBOMe	N-(2-methoxybenzyl)-1-(2-methoxy-4,5-methylenedioxyphenyl)-2-aminoethane		2-methoxy-4,5-methylenedioxy	H	2-methoxyphenyl
	MDBZ	N-benzyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane	65033-29-6	3,4-methylenedioxy	methyl	phenyl
	Clobenzorex	N-(2-chlorobenzyl)-1-phenyl-2-aminopropane	13364-32-4	H	methyl	2-chlorophenyl
	4-EA-NBOMe	N-(2-methoxybenzyl)-1-(4-ethylphenyl)-2-aminopropane		4-ethyl	methyl	2-methoxyphenyl
	5-APB-NBOMe	N-(2-methoxybenzyl)-1-(benzofuran-5-yl)-2-aminopropane		benzofuran-5-yl instead of phenyl	methyl	2-methoxyphenyl

Related compounds

Similar compounds with related structures are also known including;

Chemical structure	Common name	Chemical name	CAS number
	25B-N1POMe	N-[1-(2-methoxyphenyl)ethyl]-2,5-dimethoxy-4-bromophenethylamine	1335331-49-1 (R) 1335331-51-5 (S)
	2C-B-AN [49] [50]	2-phenyl-2-[2-(2,5-dimethoxy-4-bromophenyl)ethylamino]acetonitrile
	25B-N(BOMe)2	2-(4-Bromo-2,5-dimethoxyphenyl)-N,N-bis(2-methoxybenzyl)ethan-1-amine
	25CN-N3DHBF [51]	4-(2-[(2,3-dihydro-1-benzofuran-3-yl)amino]ethyl)-2,5-dimethoxybenzonitrile
	2CBCB-NBOMe	N-[(3-bromo-2,5-dimethoxy-bicyclo[4,2,0]octa-1,3,5-trien-7-yl)methyl]-1-(2-methoxyphenyl)methanamine	1354634-09-5
	2CBFly-NBOMe	N-(2-methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane	1335331-42-4
	2C-B-DRAGONFLY-NBOH	N-(2-hydroxybenzyl)-1-(8-bromobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane	1335331-45-7
	2C-B-FLY-NB2EtO5Cl [52]	N-(2-ethoxy-5-chlorobenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane
	DMBMPP	(S,S)-2-(2,5-dimethoxy-4-bromobenzyl)-6-(2-methoxyphenyl)piperidine	1391499-52-7
	25B-NAcPip	2-{[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]amino}-1-(piperidin-1-yl)ethanone
	ZDCM-04	1,3-dimethyl-7-{2-[1-(2,5-dimethoxy-4-chlorophenyl)propan-2-ylamino]ethyl}purine-2,6-dione
	RH-34	3-[2-(2-methoxybenzylamino)ethyl]-1H-quinazoline-2,4-dione	1028307-48-3
	5-MeO-T-NBOMe [53]	N-(2-methoxybenzyl)-5-methoxytryptamine	1335331-37-7
	5MT-NB3OMe	N-(3-methoxybenzyl)-5-methoxytryptamine	1648553-42-7

Legality

United Kingdom

A large number of substances in the 25-NB class are Class A drugs in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971 ^[54] or are otherwise covered by the Psychoactive Substances Act 2016. ^[55]

See also

• 2C family
• DOx family
• List of miscellaneous 5-HT2A receptor agonists

Notes

1. The potency of N-benzylphenethylamines via buccal, sublingual, or nasal absorption is 50-100 greater (by weight) than oral route compared to the parent 2C-x compounds. ^[32] Researchers hypothesize the low oral metabolic stability of N-benzylphenethylamines is likely causing the low bioavailability on the oral route, although the metabolic profile of this compounds remains unpredictable; therefore researchers state that the fatalities linked to these substances may partly be explained by differences in the metabolism between individuals. ^[32]

External links

• VICE In-house Chemist Hamilton Morris on the Dangers of the NBOMe Hallucinogen

References

1. Poulie CB, Jensen AA, Halberstadt AL, Kristensen JL (December 2020). "DARK Classics in Chemical Neuroscience: NBOMes". ACS Chemical Neuroscience. 11 (23): 3860–3869. doi:10.1021/acschemneuro.9b00528. PMC   9191638 . PMID   31657895. S2CID   204952449.
2. Adam H (18 January 2017). "Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens". Neuropharmacology of New Psychoactive Substances. Current Topics in Behavioral Neurosciences. Vol. 32. Springer. pp. 283–311. doi:10.1007/7854_2016_64. ISBN   978-3-319-52444-3. PMID   28097528.
3. Jolanta Z, Monika K, and Piotr A (26 February 2020). "NBOMes–Highly Potent and Toxic Alternatives of LSD". Frontiers in Neuroscience. 14: 78. doi: 10.3389/fnins.2020.00078 . PMC   7054380 . PMID   32174803. Recently, a new class of psychedelic compounds named NBOMe (or 25X-NBOMe) has appeared on the illegal drug market. NBOMes are analogs of the 2C family of phenethylamine drugs, originally synthesized by Alexander Shulgin, that contain a N-(2-methoxy)benzyl substituent. The most frequently reported drugs from this group are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. NBOMe compounds are ultrapotent and highly efficacious agonists of serotonin 5-HT2A and 5-HT2C receptors (Ki values in low nanomolar range) with more than 1000-fold selectivity for 5-HT2A compared with 5-HT1A. They display higher affinity for 5-HT2A receptors than their 2C counterparts and have markedly lower affinity, potency, and efficacy at the 5-HT2B receptor compared to 5-HT2A or 5-HT2C.
4. Pertz HH, Rheineck A, Elz S (1999-01-01). "N-Benzylated derivatives of the hallucinogenic drugs mescaline and escaline as partial agonists at rat vascular 5-HT2A receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 359: R29. Archived from the original on September 25, 2015.
5. Heim R (February 28, 2010). Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts (Thesis) (in German). Berlin: Freie Univ. Retrieved 2013-05-10.
6. Silva M (2009). Theoretical study of the interaction of agonists with the 5-HT2A receptor (Ph.D. thesis). Universität Regensburg.
7. Hansen M (2011). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen.
8. Silva ME, Heim R, Strasser A, Elz S, Dove S (January 2011). "Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor". Journal of Computer-Aided Molecular Design. 25 (1): 51–66. Bibcode:2011JCAMD..25...51S. CiteSeerX   10.1.1.688.2670 . doi:10.1007/s10822-010-9400-2. PMID   21088982. S2CID   3103050.
9. Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)" (PDF). Neuropharmacology. 99: 546–553. doi:10.1016/j.neuropharm.2015.08.034. PMID   26318099. S2CID   10382311.
10. Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, et al. (March 2014). "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience. 5 (3): 243–249. doi:10.1021/cn400216u. PMC   3963123 . PMID   24397362.
11. Lipow M, Kaleem SZ, Espiridion E (2022-03-30). "NBOMe Toxicity and Fatalities: A Review of the Literature". Transformative Medicine. 1 (1): 12–18. doi: 10.54299/tmed/msot8578 . ISSN   2831-8978. S2CID   247888583.
12. Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (December 2018). "Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors". Biochem Pharmacol. 158: 27–34. doi:10.1016/j.bcp.2018.09.024. PMC   6298744 . PMID   30261175.
13. Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)" (PDF). Neuropharmacology. 99: 546–553. doi:10.1016/j.neuropharm.2015.08.034. PMID   26318099.
14. Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID   26791601.
15. Gil-Martins E, Barbosa DJ, Borges F, Remião F, Silva R (June 2025). "Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?". Toxicol Rep. 14: 101890. Bibcode:2025ToxR...1401890G. doi:10.1016/j.toxrep.2025.101890. PMC   11762925 . PMID   39867514.
16. Custodio RJ, Sayson LV, Botanas CJ, Abiero A, You KY, Kim M, et al. (November 2020). "25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential". Addict Biol. 25 (6): e12850. doi:10.1111/adb.12850. PMID   31749223.
17. Seo JY, Hur KH, Ko YH, Kim K, Lee BR, Kim YJ, et al. (October 2019). "A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents". Brain Res Bull. 152: 19–26. doi:10.1016/j.brainresbull.2019.07.002. PMID   31279579.
18. Zawilska JB, Kacela M, Adamowicz P (2020). "NBOMes-Highly Potent and Toxic Alternatives of LSD". Front Neurosci. 14: 78. doi: 10.3389/fnins.2020.00078 . PMC   7054380 . PMID   32174803.
19. Kim YJ, Ma SX, Hur KH, Lee Y, Ko YH, Lee BR, et al. (April 2021). "New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents". Arch Toxicol. 95 (4): 1413–1429. Bibcode:2021ArTox..95.1413K. doi:10.1007/s00204-021-02980-x. PMID   33515270. 25N-NBOMe and other 2C drug derivatives similarly increased p-DAT levels in the NAc and striatum of mice (Seo et al. 2019). [...] increased p-DAT levels lead to an increase in dopamine release, which contribute to elevated dopamine levels.
20. Herian M, Skawski M, Wojtas A, Sobocińska MK, Noworyta K, Gołembiowska K (August 2021). "Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe". Psychopharmacology (Berl). 238 (8): 2349–2364. doi:10.1007/s00213-021-05860-5. PMC   8292280 . PMID   34032876.
21. Sean I, Joe R, Jennifer S, and Shaun G (28 March 2022). "A cluster of 25B-NBOH poisonings following exposure to powder sold as lysergic acid diethylamide (LSD)". Clinical Toxicology . 60 (8): 966–969. doi:10.1080/15563650.2022.2053150. PMID   35343858. S2CID   247764056.
22. Amy E, Katherine W, John R, Sonyoung K, Robert J, Aaron J (December 2018). "Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors". Biochemical Pharmacology. 158: 27–34. doi:10.1016/j.bcp.2018.09.024. PMC   6298744 . PMID   30261175.
23. Lipow M, Kaleem SZ, Espiridion E (30 March 2022). "NBOMe Toxicity and Fatalities: A Review of the Literature". Transformative Medicine. 1 (1): 12–18. doi: 10.54299/tmed/msot8578 . ISSN   2831-8978. S2CID   247888583.
24. Micaela T, Sabrine B, Raffaella A, Giorgia C, Beatrice M, Tatiana B, et al. (21 April 2022). "Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs". Front Psychiatry. 13: 875722. doi: 10.3389/fpsyt.2022.875722 . PMC   9069068 . PMID   35530025.
25. Cristina M, Matteo M, Nicholas P, Maria C, Micaela T, Raffaella A, et al. (12 December 2019). "Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe". Frontiers in Pharmacology. 10: 1406. doi: 10.3389/fphar.2019.01406 . PMC   6921684 . PMID   31915427.
26. Anna R, Dino L, Julia R, Daniele B, Marius H, Matthias L (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)". Neuropharmacology. 99: 546–553. doi:10.1016/j.neuropharm.2015.08.034. ISSN   1873-7064. PMID   26318099. S2CID   10382311.
27. David W, Roumen S, Andrew C, Paul D (6 February 2015). "Prevalence of use and acute toxicity associated with the use of NBOMe drugs". Clinical Toxicology. 53 (2): 85–92. doi:10.3109/15563650.2015.1004179. PMID   25658166. S2CID   25752763.
28. Humston C, Miketic R, Moon K, Ma P, Tobias J (2017-06-05). "Toxic Leukoencephalopathy in a Teenager Caused by the Recreational Ingestion of 25I-NBOMe: A Case Report and Review of Literature". Journal of Medical Cases. 8 (6): 174–179. doi: 10.14740/jmc2811w . ISSN   1923-4163.
29. Justin P, Stephen R, Kylin A, Alphonse P, Michelle P (2015). "Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper". Journal of Analytical Toxicology. 39 (8): 617–623. doi:10.1093/jat/bkv073. PMC   4570937 . PMID   26378135.
30. Morini L, Bernini M, Vezzoli S, Restori M, Moretti M, Crenna S, et al. (October 2017). "Death after 25C-NBOMe and 25H-NBOMe consumption". Forensic Science International. 279: e1 –e6. doi:10.1016/j.forsciint.2017.08.028. PMID   28893436.
31. Byard RW, Cox M, Stockham P (November 2016). "Blunt Craniofacial Trauma as a Manifestation of Excited Delirium Caused by New Psychoactive Substances". Journal of Forensic Sciences. 61 (6): 1546–1548. doi:10.1111/1556-4029.13212. PMID   27723094. S2CID   4734566.
32. Sabastian LP, Christoffer B, Martin H, Martin AC, Jan K, Jesper LK (14 February 2014). "Correlating the Metabolic Stability of Psychedelic 5-HT2A Agonists with Anecdotal Reports of Human Oral Bioavailability". Neurochemical Research. 39 (10): 2018–2023. doi:10.1007/s11064-014-1253-y. PMID   24519542. S2CID   254857910.
33. Boris D, Cristian C, Marcelo K, Edwar F, Bruce KC (August 2016). "Analysis of 25 C NBOMe in Seized Blotters by HPTLC and GC–MS". Journal of Chromatographic Science. 54 (7): 1153–1158. doi:10.1093/chromsci/bmw095. PMC   4941995 . PMID   27406128.
34. Francesco SB, Ornella C, Gabriella A, Giuseppe V, Rita S, Flaminia BP, et al. (3 July 2014). "25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug". BioMed Research International. 2014: 734749. doi: 10.1155/2014/734749 . PMC   4106087 . PMID   25105138.
35. Adam JP, Simon HT, Simon LH (September 2021). "Pharmacology and toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) hallucinogens". Novel Psychoactive Substances: Classification, Pharmacology and Toxicology (2 ed.). Academic Press. pp. 279–300. doi:10.1016/B978-0-12-818788-3.00008-5. ISBN   978-0-12-818788-3. S2CID   240583877.
36. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, et al. (Dec 2000). "Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications". Circulation. 102 (23): 2836–41. doi: 10.1161/01.CIR.102.23.2836 . PMID   11104741.
37. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, et al. (Jan 2000). "Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine". Molecular Pharmacology. 57 (1): 75–81. doi:10.1016/S0026-895X(24)26444-0. PMID   10617681.
38. Roth BL (Jan 2007). "Drugs and valvular heart disease". The New England Journal of Medicine. 356 (1): 6–9. doi:10.1056/NEJMp068265. PMID   17202450.
39. Xu P, Qiu Q, Li H, Yan S, Yang M, Naman CB, et al. (26 February 2019). "25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro". Neurotoxicity Research. 35 (4): 993–998. doi:10.1007/s12640-019-0012-x. PMID   30806983. S2CID   255763701.
40. Álvarez-Alarcón N, Osorio-Méndez JJ, Ayala-Fajardo A, Garzón-Méndez WF, Garavito-Aguilar ZV (2021). "Zebrafish and Artemia salina in vivo evaluation of the recreational 25C-NBOMe drug demonstrates its high toxicity". Toxicology Reports. 8: 315–323. Bibcode:2021ToxR....8..315A. doi:10.1016/j.toxrep.2021.01.010. ISSN   2214-7500. PMC   7868744 . PMID   33598409.
41. Michael Robert Braden (2007). "Towards a biophysical understanding of hallucinogen action". Dissertation: 1–176.
42. Nichols DE (2012). "Structure-activity relationships of serotonin 5-HT2A agonists". Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 1 (5): 559–579. doi: 10.1002/wmts.42 .
43. Leth-Petersen S, Petersen IN, Jensen AA, Bundgaard C, Bæk M, Kehler J, et al. (November 2016). "5-HT_2A/5-HT_2C Receptor Pharmacology and Intrinsic Clearance of N-Benzylphenethylamines Modified at the Primary Site of Metabolism". ACS Chemical Neuroscience. 7 (11): 1614–1619. doi:10.1021/acschemneuro.6b00265. PMID   27564969.
44. Prabhakaran J, Solingapuram Sai KK, Zanderigo F, Rubin-Falcone H, Jorgensen MJ, Kaplan JR, et al. (January 2017). "In vivo evaluation of [¹⁸F]FECIMBI-36, an agonist 5-HT_2A/2C receptor PET radioligand in nonhuman primate". Bioorganic & Medicinal Chemistry Letters. 27 (1): 21–23. doi:10.1016/j.bmcl.2016.11.043. PMC   5348621 . PMID   27889455.
45. Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, et al. (January 2013). "Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands". ACS Chemical Neuroscience. 4 (1): 96–109. doi:10.1021/cn3000668. PMC   3547484 . PMID   23336049.
46. Wallach J, et al. Selective, Partial and Arrestin-Biased 5-HT2A Agonists with Utility in Various Disorders. Patent WO 2022/241006
47. Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD. Identification of 5-HT2A Receptor Signaling Pathways Responsible for Psychedelic Potential. bioRxiv 2023 Jul 31:2023.07.29.551106. doi : 10.1101/2023.07.29.551106 PMID   37577474
48. Kruegel AC. Phenalkylamines and Methods of Making and Using the Same. Patent WO 2022/192781
49. Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion. Nachtschatten Verlag AG. p. 843. ISBN   978-3-03788-700-4.
50. Elliott SP, Holdbrook T, Brandt SD (May 2020). "Prodrugs of New Psychoactive Substances (NPS): A New Challenge" (PDF). Journal of Forensic Sciences. 65 (3): 913–920. doi:10.1111/1556-4029.14268. PMID   31943218. S2CID   210335207.
51. Bolinger AA, et al. The Serotonin 5-HT2A Receptor as an Evolving Neurotherapeutic Target. Medicinal Chemistry Reviews 2023; 58(3): 53-81. doi : 10.1021/mc-2023-vol58.ch03
52. Richter LH, Menges J, Wagmann L, Brandt SD, Stratford A, Westphal F, et al. (2020). "In vitro toxicokinetics and analytical toxicology of three novel NBOMe derivatives: Phase I and II metabolism, plasma protein binding, and detectability in standard urine screening approaches studied by means of hyphenated mass spectrometry" (PDF). Forensic Toxicology. 38: 141–159. doi:10.1007/s11419-019-00498-7. S2CID   202879918.
53. Nichols DE, Sassano MF, Halberstadt AL, Klein LM, Brandt SD, Elliott SP, et al. (July 2015). "N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues". ACS Chemical Neuroscience. 6 (7): 1165–1175. doi:10.1021/cn500292d. PMC   4505863 . PMID   25547199.
54. "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". www.legislation.gov.uk.
55. "Psychoactive Substances Act 2016". www.legislation.gov.uk.